Recordati Industria Chimica e Farma

CVC, together with Groupe Bruxelles Lambert, made a cash offer of €10.7 billion for the Italian pharmaceutical group Recordati with the aim of taking the company private. The announcement lifted CVC’s share price by about 3.3% on Friday, marking its best trading day since the end of April. RBC analysts see the rationale for the deal in increased investment in research and development and in future mergers and acquisitions. » Más en de.investing.com

Recordati reports Q1 2026 sales of €730m (+4.9%) and an EBITDA of €284m with a margin of 39.7%. Adjusted net profit was €188m (+7.2%); the US business grew by 25.1%, while negative currency effects weighed on sales by 4.3%. The shares rose 3.39% after the figures; for 2026 the company expects net sales between €2.73bn and €2.80bn and EBITDA of €995m to €1.03bn. » Más en de.investing.com

CVC Capital Partners is considering, in the event of a successful takeover of Recordati for €10.9 billion, selling individual business units—specifically the rare diseases division—and other assets. The firm aims to take Recordati private after the acquisition to gain greater flexibility for a realignment and to unlock value. Plans are at an early stage and details may still change. » Más en de.investing.com